RIPK1 and myeloid sarcoma: Yoshikawa et al. [200] discovered 7-oxo-2,4,5,7-tetrahydro-6H-pyrazolo [3,4-c]pyridine, a novel class of RIPK1 inhibitors with nanomolar potency as well as BBB permeability, which efficiently mitigated disease progression in an EAE mice model of MS.